Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1996 Apr;49(4):329–332. doi: 10.1136/jcp.49.4.329

beta hCG as a prognostic marker in adenocarcinoma of the prostate.

M T Sheaff 1, J E Martin 1, D F Badenoch 1, S I Baithun 1
PMCID: PMC500461  PMID: 8655711

Abstract

AIMS: To assess the importance of immunohistological detection of beta-human chorionic gonadotrophin (beta hCG) in localised prostatic adenocarcinoma with regard to prognosis and clinical applications. METHODS: Eighty consecutive cases of clinically localised adenocarcinoma of the prostate were studied retrospectively. Immunohistological analysis on formalin fixed, paraffin wax embedded prostate tissue from transurethral resections was related to clinical outcome and survival. Prognosis was also related to tumour grade. RESULTS: beta hCG was detected in 12 cases. Nine of these patients were found to have metastases (75%) at follow up and 11 (92%) were dead within 18 months. There was no correlation with grade and prognosis in this group. Of the 68 beta hCG negative cases, 21 had developed metastases (31%) and 25 (37%) had died within 18 months. In the beta hCG negative group there was an association between histological grade and survival. CONCLUSION: The demonstration of beta hCG in prostatic adenocarcinoma identifies a group of patients with poor prognosis, irrespective of histological grade. This additional information will be extremely valuable in the subsequent clinical management of such patients.

Full text

PDF
329

Images in this article

330Image
on p.330
330Image
on p.330

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrahamsson P. A., Wadström L. B., Alumets J., Falkmer S., Grimelius L. Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract. 1987 Jun;182(3):298–307. doi: 10.1016/S0344-0338(87)80065-1. [DOI] [PubMed] [Google Scholar]
  2. Beastall G. H., Cook B., Rustin G. J., Jennings J. A review of the role of established tumour markers. Ann Clin Biochem. 1991 Jan;28(Pt 1):5–18. doi: 10.1177/000456329102800102. [DOI] [PubMed] [Google Scholar]
  3. Bostwick D. G., Dousa M. K., Crawford B. G., Wollan P. C. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pathol. 1994 Dec;18(12):1240–1246. doi: 10.1097/00000478-199412000-00007. [DOI] [PubMed] [Google Scholar]
  4. Broder L. E., Weintraub B. D., Rosen S. W., Cohen M. H., Tejada F. Placental proteins and their subunits as tumor markers in prostatic carcinoma. Cancer. 1977 Jul;40(1):211–216. doi: 10.1002/1097-0142(197707)40:1<211::aid-cncr2820400133>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  5. Campo E., Palacin A., Benasco C., Quesada E., Cardesa A. Human chorionic gonadotropin in colorectal carcinoma. An immunohistochemical study. Cancer. 1987 May 1;59(9):1611–1616. doi: 10.1002/1097-0142(19870501)59:9<1611::aid-cncr2820590915>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  6. Daehlin L. On the effects of oestrogen in the male. Some effects of different oestrogenic substances in rats and men with prostatic carcinoma. Scand J Urol Nephrol Suppl. 1985;91:1–44. [PubMed] [Google Scholar]
  7. Fetissof F., Bruandet P., Arbeille B., Penot J., Marboeuf Y., Le Roux J., Guilloteau D., Beaulieu J. L. Calcitonin-secreting carcinomas of the prostate. An immunohistochemical and ultrastructural analysis. Am J Surg Pathol. 1986 Oct;10(10):702–710. doi: 10.1097/00000478-198610000-00006. [DOI] [PubMed] [Google Scholar]
  8. Fox S. B., Persad R. A., Coleman N., Day C. A., Silcocks P. B., Collins C. C. Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma. Br J Urol. 1994 Aug;74(2):214–220. doi: 10.1111/j.1464-410x.1994.tb16589.x. [DOI] [PubMed] [Google Scholar]
  9. Fukutani K., Libby J. M., Panko W. B., Scardino P. T. Human chorionic gonadotropin detected in urinary concentrates from patients with malignant tumors of the testis, prostate, bladder, ureter and kidney. J Urol. 1983 Jan;129(1):74–77. doi: 10.1016/s0022-5347(17)51926-6. [DOI] [PubMed] [Google Scholar]
  10. Iles R. K., Chard T. Human chorionic gonadotropin expression by bladder cancers: biology and clinical potential. J Urol. 1991 Mar;145(3):453–458. doi: 10.1016/s0022-5347(17)38367-2. [DOI] [PubMed] [Google Scholar]
  11. Jenkins B. J., Martin J. E., Baithun S. I., Zuk R. J., Oliver R. T., Blandy J. P. Prediction of response to radiotherapy in invasive bladder cancer. Br J Urol. 1990 Apr;65(4):345–348. doi: 10.1111/j.1464-410x.1990.tb14753.x. [DOI] [PubMed] [Google Scholar]
  12. Kiernan M., Gaffney E. F. The endocrine-paracrine cells of von Brunn's nests and glandular metaplasia in the supramontanal prostatic urethra. Histopathology. 1990 Apr;16(4):365–369. doi: 10.1111/j.1365-2559.1990.tb01140.x. [DOI] [PubMed] [Google Scholar]
  13. Kokuho M., Yoshiki T., Hamaguchi A., Okada Y., Tomoyoshi T., Higuchi K. [Immunohistochemical study of c-erbB-2 proto-oncogene product in prostatic cancer]. Nihon Hinyokika Gakkai Zasshi. 1993 Oct;84(10):1872–1878. doi: 10.5980/jpnjurol1989.84.1872. [DOI] [PubMed] [Google Scholar]
  14. Martin J. E., Jenkins B. J., Zuk R. J., Oliver R. T., Baithun S. I. Human chorionic gonadotrophin expression and histological findings as predictors of response to radiotherapy in carcinoma of the bladder. Virchows Arch A Pathol Anat Histopathol. 1989;414(3):273–277. doi: 10.1007/BF00822032. [DOI] [PubMed] [Google Scholar]
  15. McDonnell T. J., Troncoso P., Brisbay S. M., Logothetis C., Chung L. W., Hsieh J. T., Tu S. M., Campbell M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992 Dec 15;52(24):6940–6944. [PubMed] [Google Scholar]
  16. McManus L. M., Naughton M. A., Martinez-Hernandez A. Human chorionic gonadotropin in human neoplastic cells. Cancer Res. 1976 Sep;36(9 Pt 2):3476–3481. [PubMed] [Google Scholar]
  17. Oliver R. T., Stephenson C., Collino C. E., Parkinson M. C. Clinicopathological significance of immunoreactive beta-hCG production by bladder cancer. Mol Biother. 1988;1(1):43–45. [PubMed] [Google Scholar]
  18. Papapetrou P. D., Sakarelou N. P., Braouzi H., Fessas P. Ectopic production of human chorionic gonadotropin (hCG) by neoplasms: the value of measurements of immunoreactive hCG in the urine as a screening procedure. Cancer. 1980 May 15;45(10):2583–2592. doi: 10.1002/1097-0142(19800515)45:10<2583::aid-cncr2820451018>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  19. Purnell D. M., Heatfield B. M., Trump B. F. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen. Cancer Res. 1984 Jan;44(1):285–292. [PubMed] [Google Scholar]
  20. Segal N. H., Cohen R. J., Haffejee Z., Savage N. BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med. 1994 Jun;118(6):616–618. [PubMed] [Google Scholar]
  21. Shah V. M., Newman J., Crocker J., Antonakopoulos G. N., Chapple C. R., Collard M. J. Production of beta-human chorionic gonadotropin by prostatic adenocarcinoma and transitional cell carcinoma of the upper urinary tract. Br J Exp Pathol. 1987 Dec;68(6):871–878. [PMC free article] [PubMed] [Google Scholar]
  22. Yamanaka N., Kawabata G., Morisue K., Hazama M., Nishimura R. [Urinary hCG beta-core fragment as a tumor marker for bladder cancer]. Nihon Hinyokika Gakkai Zasshi. 1993 Apr;84(4):700–706. doi: 10.5980/jpnjurol1989.84.700. [DOI] [PubMed] [Google Scholar]
  23. di Sant'Agnese P. A. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer. 1992 Jul 1;70(1 Suppl):254–268. doi: 10.1002/1097-0142(19920701)70:1+<254::aid-cncr2820701312>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES